2006
Multicenter Open-label Extension Trial of Long-term Treatment with Gefitinib (IRESSA®)
Nakagawa K, Ranson M, Yano S, Tamura T, Saka H, Imamura F, Yokoyama A, Matsui K, Jiang H, Herbst R. Multicenter Open-label Extension Trial of Long-term Treatment with Gefitinib (IRESSA®). Haigan 2006, 46: 345. DOI: 10.2482/haigan.46.345.Peer-Reviewed Original ResearchProgression-free survivalLong-term treatmentNew safety issuesExtension trialOpen-label extension trialSkin-related adverse eventsMedian overall survivalMajority of patientsLong-term safetyGefitinib monotherapyAdvanced NSCLCAdverse eventsOverall survivalParent trialClinical benefitGefitinib treatmentSafety profileClinical trialsClinical studiesPatientsGefitinibIdeal 1TrialsSafety issuesSurvival
2003
Dose-comparative monotherapy trials of ZD1839 in previously treated non–small cell lung cancer patients
Herbst RS. Dose-comparative monotherapy trials of ZD1839 in previously treated non–small cell lung cancer patients. Seminars In Oncology 2003, 30: 30-38. PMID: 12644982, DOI: 10.1053/sonc.2003.50030.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerSymptom improvement rateTumor response rateDay groupSolid tumorsChemotherapy regimensIDEAL-2Ideal 1Lung cancerClinical trialsStage IIIResponse rateNon-small cell lung cancer patientsEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsAdvanced unresectable stage IIIMedian progression-free survivalObjective tumor response rateCell lung cancer patientsImprovement rateSelective epidermal growth factor receptor tyrosine kinase inhibitorReceptor tyrosine kinase inhibitorsPhase I clinical trialIressa Dose Evaluation